NDA 219616 · Verastem INC
Avmapki Fakzynja CO-Pack (Copackaged)
Avutometinib Potassium, Defactinib Hydrochloride · Oral
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, May 8, 2025: To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
Last checked: Nov 19, 2026Latest source record: May 8, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
May 8, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
27
1 Phase 3, 12 recruiting
FAERS reports
1,125
175 serious, 37 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 1, 2025.
AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 , 14 )
Mechanism: Avutometinib Avutometinib is a MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines harboring KRAS mutations. Treatment of cancer cells with avutometinib increased the level of phosphorylated focal adhesion kinase (FAK). Defactinib Defactinib is an inhibitor of FAK and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 8, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
1 products under this application
- AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) · AVUTOMETINIB POTASSIUM EQ 0.8MG BASE; DEFACTINIB HYDROCHLORIDE EQ 200MG BASE · CAPSULE, TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avutometinib" as an intervention, any sponsor and status, largest first.
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerPivotal-lookingRecruiting
Verastem, Inc.Industry
NCT06072781 · 270 participants (planned) · Start Mar 18, 2024 · Primary completion Oct 15, 2028
Drug: avutometinib; Defactinib and 4 more · For: Low Grade Serous Ovarian Cancer
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 105 sites in all
- A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS MutationPivotal-lookingActive, not recruiting
Verastem, Inc.Industry
NCT04625270 · 225 participants (planned) · Start Dec 21, 2020 · Primary completion Nov 15, 2024
Drug: avutometinib (VS-6766); avutometinib (VS-6766) and defactinib · For: Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer
Sites: Scottsdale, Arizona; Santa Barbara, California; New Haven, Connecticut · 47 sites in all
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT06630260 · 182 participants (planned) · Start Nov 15, 2024 · Primary completion Sep 30, 2029
Drug: Avutometinib; Defactinib and 1 more · For: Glioblastoma Multiforme (GBM); Glioblastoma Multiform (Grade IV Astrocytoma); Diffuse Hemispheric Glioma, H3 G34-Mutant and 1 more
Sites: Cambridge, United Kingdom; Sutton, United Kingdom · 3 sites in all
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruiting
Verastem, Inc.Industry
NCT05074810 · 153 participants (planned) · Start Apr 12, 2022 · Primary completion Jun 2026
Drug: avutometinib and sotorasib; avutometinib and sotorasib and defactinib · For: Non Small Cell Lung Cancer; KRAS Activating Mutation
Sites: Boulder, Colorado; Washington D.C., District of Columbia; Arlington Heights, Illinois · 35 sites in all
Verastem, Inc.Industry
NCT04620330 · 90 participants · Start Dec 31, 2020 · Primary completion Aug 29, 2023
Drug: avutometinib (VS-6766); avutometinib (VS-6766) and Defactinib · For: Non Small Cell Lung Cancer; KRAS Activating Mutation
Sites: Duarte, California; Aurora, Colorado; Lone Tree, Colorado · 45 sites in all
- VS-6766+Abema+Fulv in Met HR+/HER- BCRecruiting
Adrienne G. WaksAcademic, hospital or other
NCT05608252 · 63 participants (planned) · Start Feb 23, 2023 · Primary completion Dec 31, 2027
Drug: VS-6766; Abemaciclib and 1 more · For: Breast Cancer; Hormone Receptor-positive Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer
Sites: Boston, Massachusetts · 3 sites in all
University of OklahomaAcademic, hospital or other
NCT05512208 · 55 participants (planned) · Start Feb 6, 2023 · Primary completion Dec 2027
Drug: Avutometinib (VS-6766) + defactinib · For: Endometrioid Cancer; Mucinous Ovarian Cancer; High Grade Serous Ovarian Cancer and 2 more
Sites: Orlando, Florida; New Orleans, Louisiana; Albuquerque, New Mexico · 4 sites in all
University of ChicagoAcademic, hospital or other
NCT05200442 · 53 participants (planned) · Start Aug 22, 2022 · Primary completion May 1, 2027
Drug: VS-6766/avutometinib; Cetuximab · For: Colorectal Cancer; Colorectal Adenocarcinoma; Colorectal Cancer Metastatic and 2 more
Sites: Chicago, Illinois
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use191
- fatigue168
- nausea156
- diarrhoea119
- rash116
- product dose omission issue99
- vomiting79
- vision blurred67
- peripheral swelling66
- acne57
- pruritus54
- dry skin46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 288 |
| 2026 | 837 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, et al. · J Clin Oncol 2025 · Clinical Trial, Phase II, Randomized Controlled Trial
- Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.
Banerjee S, Krebs MG, Greystoke A, et al. · Nat Med 2025 · Clinical Trial, Phase I
- Window of opportunity study measuring defactinib and avutometinib delivery in glioblastomas.
Del Valle MM, Colon EM, Kettimuthu K, et al. · Cancer Chemother Pharmacol 2026 · Clinical Trial, Phase I
- Long-term efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer: Results of a 2-year follow-up of ENGOT-OV60/GOG-3052/RAMP 201.
Grisham RN, Van Nieuwenhuysen E, Santin AD, et al. · Gynecol Oncol 2026 · Clinical Trial, Phase II, Multicenter Study
- Avutometinib, Abemaciclib, and Fulvestrant in Patients with HR+/HER2- Metastatic Breast Cancer Previously Treated with CDK4/6 Inhibitor: A Single-Arm Phase I Trial.
Waks AG, Segui E, Li T, et al. · Clin Cancer Res 2026 · Clinical Trial, Phase I
Sponsor: Verastem INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.